The evidence base for NMN
Nicotinamide mononucleotide (NMN) is a bioactive nucleotide and a direct intermediate in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). While trace amounts are present in dietary sources such as edamame, broccoli, and cabbage, the clinical research base focuses on targeted supplementation to address age-related systemic NAD+ decline. This corpus evaluates the evidence regarding NMN's mechanisms of action in restoring mitochondrial function, supporting metabolic homeostasis, and maintaining vascular health.
Evidence at a glance
Bioavailability
MIB-626, an oral formulation of a microcrystalline unique polymorph of β-nicotinamide mononucleotide, increases circulating nicotinamide adenine dinucleotide and its metabolome in middle-aged and older adults
Randomised, double-blind, placebo-controlled multiple-ascending-dose PK/PD trial in humans with validated LC–MS/MS analytics and pharmaceutical-grade study product; small sample (n=32), narrow age band (55–80), and 14-day duration constrain generalisability.
Tier 2The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans
Randomised, open-label, placebo-controlled human trial with pre-registered primary endpoint (ClinicalTrials.gov NCT05517122) in 65 healthy adults, with validated LC–MS/MS analytics and complementary ex vivo microbiome and whole-blood mechanistic work; open-label design and healthy-only population limit inference to disease states.